Position in PFE
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$1,436,081
-$88,409 QoQ
Shares Held
59,638
+9.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
1.37%
of 13F equity value
Holder Rank
#1,111
of 2,821 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 23%
Shared 77%
None 0%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Lynx Investment Advisory holds $4,458,205 across 7 Drug Manufacturers - General names. PFE ranks #1 (32.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
This page
|
59,638 | $1,436,081 | |
| 2 | ABBV |
AbbVie Inc.
|
2,938 | $739,317 | |
| 3 | JNJ |
Johnson & Johnson
|
2,594 | $658,796 | |
| 4 | MRK |
Merck & Co., Inc.
|
4,906 | $630,421 | |
| 5 | AZN |
Astrazeneca PLC
|
2,144 | $406,544 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,540 | $319,212 | |
| 7 | NVS |
Novartis AG
|
1,709 | $267,834 |
All Filings in PFE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,436,081 | 59,638 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $1,524,490 | 54,291 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $1,221,219 | 49,045 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $1,259,321 | 49,424 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $1,217,210 | 50,215 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $1,210,794 | 47,782 | Shares | Sole | 2025-06-16 | |
| 2024-12-31 | $826,700 | 31,161 | Shares | Other | 2025-02-11 | |
| 2024-09-30 | $789,916 | 27,295 | Shares | Other | 2024-11-04 | |
| 2024-06-30 | $768,217 | 27,456 | Shares | Other | 2024-07-09 | |
| No filing history on record for this holder in this stock. | ||||||